Skip to Content

Lentivirus

How to use a "Lentivirus" as a vehicle for reporter gene transfection of cells.

⇒Lentivirus protocol to make your own luciferase cell lines - Fast and Easy.

 

Why Viral Transduction?

Labeling cells with a genetically encoded reporter gene (firefly luciferase, red fluorescent protein, transferrin, thymidine kinase, etc.) is the number one choice for in vivo molecular imaging. As opposed to synthetic fluorescent dyes, radioisotopes or magnetic beads etc. which dilute with cell mitosis, a constitutively expressed reporter gene is the only longitudinally quantitative option. Various transfection methods to introduce foreign DNA in cells exist. A virus is nature’s own shuttle of genetic material and therefore viral infection is by far the most efficient transduction method even for resilient cell lines (Kim et al, 2004).  Multiple viral delivery systems exist (Adenovirus, Adeno-Associated Virus, Retrovirus, and Lentivirus). However, the lentivirus distinguishes itself with long term, sustained expression of transgenes. Lentiviral vectors are able to stably integrate into quiescent, non-dividing as well as dividing cells without silencing, and without producing an immune response (Dissen et al., 2009). Transgene efficiency of close to 100% has been reported (Peng et al., 2008) and lentiviruses infect a broad array of species (Craigo and Montelaro, 2010). These features allow for fast and easy DNA reporter labeling of immortal cell lines as well as primary cell lines.

 

Lentivirus - Background information.

Lentiviral vectors are based upon HIV-1. This virus excels in host cell attachment, receptor mediated entry, viral mediated reverse transcription and genome integration. Minimal immune or inflammatory responses or toxicity have been observed (Dissen et al., 2009). Through genetic engineering, safe lentiviral vector systems have been developed to generate replication incompetent viral particles.

The use of replication incompetent lentiviral particles or pseudovirus for transgene transduction is quickly becoming standard practice in life science research. Safety strategies to ensure replication-incompetency of viral particles that are generated by viral packaging kits involve: (University of Pittsburgh Guidance)
  • Separation of structural and replication genes necessary to produce viral particles onto multiple plasmids; No single plasmid contains all the genes necessary to produce packaged lentivirus.
  • Deletion of virulence and accessory genes such as the Tat gene essential for replication.  
  • Promoter disabling mutations engineered into the U3 region of the 3’ long terminal repeat render the viral particles self inactivating (SIN), providing additional safety as vectors should not be able to generate full-length vector RNA after viral integration.

Both second generation (3-plasmid) and third generation (4-plasmid) systems are available commercially. Third generation plasmids consist of 3 helper plasmids: a packaging construct, a VSV-G construct and a Rev construct, along with a Tat-independent gne transfer vector.

Most viruses can be produced and used under Biosafety level 2 conditions.


 

 

Lentiviral infection - How does it work?

Upon viral transduction, host cells are exposed to viral RNA and preformed viral enzymes such as RT and integrase etc. The viral RNA is reverse-transcribed into DNA, and a subsequent preintegration complex is actively imported into the nucleus (Bukrinsky et al., 1993), and stably integrated into the host genome (Buchschacher& Wong-Staal, 2000). One or two days after, the lentiviral genome is integrated into the host genome (Dissen et al, 2009).
 

 

Lentiviral particle / Pseudovirus - Components.

Virions consist of an envelope, a nucleocapsid, a nucleoid, and a matrix protein. The enveloped virions assume a spherical to pleomorphic shape of 80-100nm in diameter. The virion surface is covered with dense inconspicuous spikes of 8 nm in length. Viruses frequently are made to express the vesicular stomatitis virus G (VSV-G) protein in place of viral Env in order to increase cell tropism.  The viral genome is not inside the engineered lentiviral particles (only the reporter gene).  The viral genome (on a plasmid) is only present in the packaging cells.
 

 

Lentivirus: Facts and Applications.

  • Lentivirus can accommodate large inserts (up to 10kb).
  • High viral titer concentrations of 10^9 TU/ml.
  • Lentivirus can be pseudotyped.
  • Lentivirus can be used to generate stable cell lines.
  • Lentivirus permit internal promoters into the transfer vector so that the reporter genes can be expressed as inducible systems (Kim et al., 2004).
  • Lentivirus can be used for long-term expression of short hairpin RNA (shRNA) and siRNA in vitro and in vivo.
  • Lentivirus can be used for in vivo transient transgenic expression for at least 3 months.
  • Lentivirus can be used to label and track tumor cells, stem cells, white blood cells in vivo.
  • Lentivirus can be used to deliver gene therapy in vivo.

 

Lentivirus Transduction Protocol.

 For a sample protocol see Lenti-Fire™.

Lentivirus Reagents for in vivo imaging.

Lenti Fire™ – Luc2 lentiviral vector - In Vivo Imaging Solutions
Lenti-Fire™ combines the best in vivo optical imaging reporter, namely the enhanced  firefly luciferase luc2 construct  from the pGL4 plasmid with the best gene delivery system, a third generation lentiviral vector. An Ubiquitin C promoter drives high constitutive expression of the transgene (Schorpp et al., 1996) since CMV promoter silencing can occur in certain cell lines. Luc2 is an enhanced firefly luciferase construct, codon optimized for mammalian cell cytoplasmic expression. Emission peaks at 600nm in mammalian cells. Regular D-luciferin is the substrate. This is the most sensitive reporter gene for deep tissue in vivo bioluminescence imaging. Because of the high transfection efficiency of a lenti, this product makes the creation of luciferase expressing cell lines easy.
 
 
 
 

 

Lentivirus - in vivo Imaging References.

 
Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, Bata A, Campbell K, Coffee R, Gorodinsky A, Lu Z, Zhou H, Kishimoto TK, Lassota P.
PLoS One. 2010 Feb 23;5(2):e9364.
 
Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G.
Pigment Cell Melanoma Res. 2009 Jun;22(3):283-95.
 
Cao F, Xie X, Gollan T, Zhao L, Narsinh K, Lee RJ, Wu JC.
Mol Imaging Biol. 2010 Jan-Feb;12(1):15-24.
 
Steiner D, Gelovani J, Savoldo B, Robinson SN, Decker WK, Brouard N, Najjar A, Xing D, Yang H, Li S, Marini F, Zweidler-McKay PA, Bollard CM, Shpall EJ, Dotti G, Simmons PJ.
Stem Cells. 2009 Aug;27(8):1932-40
 
Zhang KX, Kim C, Chow E, Chen IS, Jia W, Rennie PS.
Breast Cancer Res Treat. 2010 Mar 16.

 

More White papers...